115 related articles for article (PubMed ID: 30704555)
1. Cardiac toxicity of combined vemurafenib and cobimetinib administration
.
Fiocchi R; Gori M; Taddei F; Trevisani L; Gallo M; Eleftheriou G
Int J Clin Pharmacol Ther; 2019 May; 57(5):259-263. PubMed ID: 30704555
[TBL] [Abstract][Full Text] [Related]
2. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
3. Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.
Hopkins AM; Van Dyk M; Rowland A; Sorich MJ
Pigment Cell Melanoma Res; 2019 Jul; 32(4):576-583. PubMed ID: 30758912
[TBL] [Abstract][Full Text] [Related]
4. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
5. Two cases of pneumonitis induced by targeted therapy.
Lafabregue E; Arnault JP; Auquier M; Magois E; Chaby G; Lok C
Melanoma Res; 2019 Aug; 29(4):441-443. PubMed ID: 31260421
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Profiling in
Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
[No Abstract] [Full Text] [Related]
7. [Vemurafenib-induced radiation recall dermatitis].
Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
[TBL] [Abstract][Full Text] [Related]
8. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
9. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
van Berge Henegouwen JM; van der Wijngaart H; Zeverijn LJ; Hoes LR; Meertens M; Huitema ADR; Devriese LA; Labots M; Verheul HMW; Voest EE; Gelderblom H
Cancer Chemother Pharmacol; 2022 Jul; 90(1):97-104. PubMed ID: 35598186
[TBL] [Abstract][Full Text] [Related]
11. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
12. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
13. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
14. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM
Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
[TBL] [Abstract][Full Text] [Related]
15. Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
Gauci ML; Laly P; Leonard-Louis S; Behin A; Gottlieb J; Madelaine-Chambrin I; Baroudjian B; Da-Meda L; Mourah S; Battistella M; Basset-Seguin N; Bagot M; Pages C; Vercellino L; Maisonobe T; Lebbé C
Melanoma Res; 2017 Oct; 27(5):511-515. PubMed ID: 28692456
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
Kouros P; Gerding H
Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
[No Abstract] [Full Text] [Related]
17. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
[TBL] [Abstract][Full Text] [Related]
20. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.
Batinac T; Hlača N; Simetić L; Valković F; Peternel S; Prpić-Massari L
Acta Derm Venereol; 2022 Feb; 102():adv00650. PubMed ID: 35146529
[No Abstract] [Full Text] [Related]
[Next] [New Search]